Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 10/20 | 0.56 |
| ▸ | RAF1 | P04049 | 9/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182955 | 0.97 | PIK3CD (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL182771 | 0.92 | PIK3CD (0.73) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL182889 | 0.90 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL182387 | 0.90 | PIK3CD (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL182895 | 0.89 | PIK3CD (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL183026 | 0.85 | PIK3CD (0.62) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL182705 | 0.85 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL182765 | 0.85 | PIK3CD (0.69) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL182536 | 0.85 | PIK3CA (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL182537 | 0.84 | PIK3CD (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| CN-101490016-A | 2,4-substituted quinazolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2009-07-22 | — | — | CN | claimed |
| EP-2049502-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | claimed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | claimed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| CN-101490016-A | 2,4-substituted quinazolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2009-07-22 | — | — | CN | disclosed |